Literature DB >> 8200940

Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.

T O Carpenter1, M A Mitnick, A Ellison, C Smith, K L Insogna.   

Abstract

Parathyroid function is described as normal in patients with phosphopenic rickets before initiation of therapy with phosphate salts; however, hyperparathyroidism is an occasional complication of treatment. We observed a higher than expected frequency of hyperparathyroidism in patients with phosphate-wasting rickets, present before treatment in some patients and, more frequently, after the onset of treatment. To better define parathyroid status in hypophosphatemic rickets, we sampled 12 affected children and 7 affected adults every 4 h for 1 day and measured PTH in assays detecting midmolecule fragments (cPTH) and intact hormone (iPTH). All children and 4 adults were receiving a vitamin D preparation and phosphate salts; 3 adults were untreated. Mean cPTH, iPTH, and nephrogenous cAMP excretions in each group of patients were greater than in controls. Exaggerated nocturnal rises in both cPTH and iPTH characterized the profile in patients. Seventeen patients demonstrated frankly elevated cPTH at night, with peak values at midnight, whereas no control individual did. Although mean iPTH values in patients increased at night, they did not exceed the upper limit of normal. Hyperparathyroidism in hypophosphatemic rickets occurs in both children and adults, may be present in untreated patients, is predominantly nocturnal, and is characterized by exaggerated secretion of midmolecule fragments. This manifestation of hypophosphatemic rickets is more widespread than currently recognized; we speculate that it may contribute to the pathogenesis of nephrocalcinosis and precede the development of tertiary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200940     DOI: 10.1210/jcem.78.6.8200940

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Familial hypophosphatemia: an unusual presentation with low back ache, heel pain, and a limp in a young man, and literature review.

Authors:  Sharon Arthur; Arvind Chopra
Journal:  Clin Rheumatol       Date:  2010-11-02       Impact factor: 2.980

2.  Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease.

Authors:  Jessica Connor; Elizabeth A Olear; Karl L Insogna; Lee Katz; Suher Baker; Raghbir Kaur; Christine A Simpson; John Sterpka; Robert Dubrow; Jane H Zhang; Thomas O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  2015-07-15       Impact factor: 5.958

3.  Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.

Authors:  Thomas O Carpenter; Elizabeth A Olear; Jane H Zhang; Bruce K Ellis; Christine A Simpson; David Cheng; Caren M Gundberg; Karl L Insogna
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

4.  A randomized controlled study of effects of dietary magnesium oxide supplementation on bone mineral content in healthy girls.

Authors:  Thomas O Carpenter; Maria C DeLucia; Jane Hongyuan Zhang; Gina Bejnerowicz; Lisa Tartamella; James Dziura; Kitt Falk Petersen; Douglas Befroy; Dorothy Cohen
Journal:  J Clin Endocrinol Metab       Date:  2006-10-03       Impact factor: 5.958

Review 5.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

Review 6.  Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Authors:  Bracha K Goldsweig; Thomas O Carpenter
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

7.  Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Authors:  Thomas O Carpenter; Karl L Insogna; Jane H Zhang; Bruce Ellis; Sherril Nieman; Christine Simpson; Elizabeth Olear; Caren M Gundberg
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

8.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

9.  Secondary hyperparathyroidism as a palpable intrathyroid parathyroid gland in a patient with hypophosphatemic osteomalacia.

Authors:  Deng-Huang Su; Kuo-Meng Liao; Ying-Chun Chang; Keh-Sung Tsai
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

10.  X-linked hypophosphatemic rickets (PHEX mutation): A case report and literature review.

Authors:  Badi Alenazi; M A Maleque Molla; Abdullah Alshaya; Mahmoud Saleh
Journal:  Sudan J Paediatr       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.